Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 8:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 3,785 matching trials from the live ClinicalTrials.gov search.
Conditions
Extensive-stage Small Cell Lung Cancer
Interventions
Durvalumab, Tremelimumab, SGI-110
Drug
Lead sponsor
Catherine Shu
Other
Eligibility
18 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Bladder Cancer Cell Transitional, Non-Muscle Invasive Bladder Cancer, Bladder Cancer, Urinary Bladder, Transitional Cell Carcinoma of the Bladder, Urinary Bladder Neoplasms, Urologic Neoplasms, Urogenital Neoplasms, Urinary Bladder Diseases, Urologic Diseases
Interventions
TSD-001
Drug
Lead sponsor
Lipac Oncology LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Tucson, Arizona • Bakersfield, California • Los Angeles, California + 2 more
Conditions
Acute Pancreatitis
Interventions
CM4620
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
3
States / cities
Charlotte, North Carolina • Cincinnati, Ohio • Memphis, Tennessee
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma, Homologous Recombination Deficiency (HRD)
Interventions
Pembrolizumab, Olaparib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Middletown, New Jersey • Montvale, New Jersey • Commack, New York + 3 more
Conditions
Uncontrolled Gout, Chronic Gout
Interventions
Pegloticase, Methotrexate (MTX)
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
Anchorage, Alaska • Glendale, Arizona • San Leandro, California + 9 more
Conditions
Healthy Subjects
Interventions
TI Inhalation Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
G(M2) Ganglioside, Tay-Sachs Disease Ganglioside, Sandhoff Disease Ganglioside
Interventions
Pyrimethamine
Drug
Lead sponsor
Exsar Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Conditions
Advanced Cancer, Metastatic Cancer
Interventions
FS120
Drug
Lead sponsor
invoX Pharma Limited
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
New Haven, Connecticut • Houston, Texas • San Antonio, Texas + 1 more
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Escalation Safety and Pharmacokinetic Study of ATX-101

NCT00618709
Conditions
Healthy
Interventions
ATX-101
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Systemic Infection
Interventions
Antibiotic
Drug
Lead sponsor
Phillip Brian Smith
Other
Eligibility
14 Days to 32 Weeks
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
10
States / cities
Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 7 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Single or Repeat Dose of G03-52-01 in Adult Subjects

NCT05348993
Conditions
Healthy, Botulinum Toxin
Interventions
G03-52-01, Placebo
Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 65 Years
Enrollment
622 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
15
States / cities
Mobile, Alabama • Tempe, Arizona • Fort Myers, Florida + 11 more
Conditions
Stage III Adult Soft Tissue Sarcoma
Interventions
Gemcitabine, Docetaxel, Pazopanib
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Burlington, Vermont
Conditions
Bacterial Infections, Intra-Abdominal Infection, Pneumonia, Bacterial, Skin Diseases, Bacterial, Skin Diseases, Infectious
Interventions
Tygacil
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
8 Years to 11 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
18
States / cities
Long Beach, California • Oakland, California • Orange, California + 15 more
Active, not recruiting Not applicable Interventional

Nurturing Care Family Navigator

NCT06859372
Conditions
Food Insecurity Among Children, Food Insecurity in Post Partum Women, Care Coordination in Primary Care, Preventive Care / Anticipatory Guidance, Retention in Care
Interventions
Nurturing Care Family Navigator
Behavioral
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Las Vegas, Nevada
Conditions
Healthy
Interventions
RSV Vaccine, Placebo
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years and older
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
9
States / cities
San Diego, California • Coral Gables, Florida • El Dorado, Kansas + 6 more
Conditions
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
Interventions
nab-sirolimus, nab-sirolimus + temozolomide, nab-sirolimus + bevacizumab, nab-sirolimus + lomustine, nab-sirolimus + marizomib (MRZ), nab-sirolimus + temozolomide + radiotherapy
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Fullerton, California • Newport Beach, California • Santa Monica, California
Active, not recruiting Phase 1Phase 2 Interventional Results available

Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia

NCT01623167
Conditions
Severe Aplastic Anemia
Interventions
Cohort 1: hATG, CsA, EPAG Day 14 to Month 6, Cohort 2: hATG, CsA, EPAG Day 14 to Month 3, Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6, Extension Cohort
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 95 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Pancreatic Cancer, Cancer of the Pancreas
Interventions
huCART-meso cells
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing

NCT03330457
Conditions
Bleeding
Interventions
Andexanet alfa (bolus), Betrixaban 80 mg PO QD, Andexanet alfa (infusion IV)
Biological · Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cypress, California
Conditions
Advanced Unresectable Solid Tumors, BRAF-mutated Tumors
Interventions
FORE8394
Drug
Lead sponsor
Fore Biotherapeutics
Industry
Eligibility
10 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
13
States / cities
Scottsdale, Arizona • Orange, California • Stanford, California + 9 more
Conditions
Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Vitamin d Deficiency, Secondary Hyperparathyroidism
Interventions
CTAP101, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
8 Years to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Columbus, Ohio • Greenville, South Carolina
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
AFP464, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Melanoma
Interventions
young TIL, Pembrolizumab, Aldesleukin, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Glioblastoma, Glioblastoma Multiforme, Glioma, Astrocytoma, Brain Tumor
Interventions
Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy, Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab
Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Los Angeles, California